Original Research Article

A qualitative study of pulmonary function tests between smokers and non-smokers in Telangana state

Farzana Mustafa1,*, Abdul Hai Mohammad2

1Dept. of Physiology, Malla Reddy Institute of Medical Sciences, Hyderabad, Telangana, India
2Deccan College of Medical Sciences, Hyderabad, Telangana, India

ARTICLE INFO

Article history:
Received 13-04-2021
Accepted 04-09-2021
Available online 01-10-2021

Keywords:
Pulmonary function test
Smokers
Non-smokers

ABSTRACT

Background: In a few examinations, low spirometric levels have been displayed to expand the achievement paces of smoking discontinuance, while different investigations have demonstrated that aspiratory work affects stopping smoking. Given the way that there are conflicting outcomes regarding this matter, we expected to research the impact of distinguishing aviation route obstacle by means of spirometry and its clarification to subjects on the achievement pace of smoking discontinuance temporarily.

Materials and Methods: The current study was led in Gandhi Medical College, Hyderabad, India, Subjects who were conceded to the smoking discontinuance out-patient facility, went through pneumonic capacity tests (PFTs) and finished somewhere around 90 days of the suspension program following their induction were remembered for the investigation.

Results: The mean age of the 563 subjects was 41.9 ± 12.1 y 340 subjects (60.4%) were male. An aggregate of 162 subjects (28.8%) went to the subsequent visits following the primary meeting. The accomplishment of smoking suspension for 90 days was 11.3% for all subjects and 39.5% for subjects who came to follow-up visits. Of the subjects with impediment on PFT; 22.8% quit smoking, while 8.4% of the subjects without block did as such (P < .001). The level of subjects with impediment on PFT was altogether higher (P < .001) and the FEV1 % (P = .005), FEV1/FVC (P < .001), and constrained expiratory stream 25–75% (P = .008) levels were fundamentally lower in the weaklings contrasted and the non-slackers. Strategic relapse investigation showed that age (P = .001) and the presence of impediment on pft (p = .029) were autonomous factors.

Conclusions: Old age and the presence of impediment on PFT increment the accomplishment of smoking end. Aspiratory work tests ought to be performed on all patients who apply to smoking end out-patient facilities, and patients ought to be educated with regards to their condition.

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

1. Introduction

COPD is one of the main sources of mortality on the planet. COPD, which was the fifth driving reason for death worldwide in 2002, is relied upon to ascend to fourth place by 2030.1 Smoking is the main perceived danger factor for COPD. Based on these discoveries, the Global Initiative for Chronic Obstructive Lung Diseases (GOLD), the American Thoracic Society, & the European Respiratory Society additionally suggest smoking end as the primary line alternative for forestalling & treating COPD.2–6 Given the way that there are opposing outcomes regarding this matter, we intended to decide the impact of distinguishing aviation route impediment by means of spirometry & imparting this data to subjects on the achievement pace of smoking end temporarily.

https://doi.org/10.18231/j.ijcap.2021.049
2394-2118© 2021 Innovative Publication, All rights reserved. 219
The best technique for smoking discontinuance is the multidisciplinary approach, which includes mental, conduct & pharmacologic therapies. According to a meta-examination, which assessed the accomplishment of smoking suspension medicines in subjects with COPD, the achievement of smoking end inside 6 a year shifted somewhere in the range of 13.7 & 34.5% for pharmacologic treatment with social therapy. Although subjects with COPD who got the suggested medicines for smoking end were relied upon to be more fruitful in smoking end because of their side effects, one investigation showed no distinction in the inspiration & accomplishment for smoking end among COPD & non-COPD subjects. According to another examination, subjects with COPD who quit smoking had lower aspiratory work test (PFT) values contrasted & non-quitters. Spirometric estimation is the main device for COPD diagnosis. Many patients with COPD find out with regards to their illness during screening tests or at smoking end facilities. In a few investigations, it has been shown that low spirometric qualities & sharing of this data with subjects increment the achievement paces of smoking cessation. Other examinations have demonstrated that imparting data to the subject after the distinguishing proof of a block on the PFT has no impact on smoking cessation. According to 2 audits, which assessed comparative examinations, there is inadequate proof for the beneficial outcomes of spirometry on the accomplishment of smoking cessation.

2. Materials and Methods

2.1. Study design

The current study was directed in Gandhi Medical College, Hyderabad, India, subjects who were conceded to the smoking end out-patient facility, went through pneumonic capacity tests (PFTs) & finished no less than 90 days of the discontinuance program following their permission were remembered for the investigation. At the main meeting, all subjects were gotten some information about their comorbid infections & smoking propensities. PFTs were performed. Subjects who had a block on PFT were educated that their condition was smoking-related, & that further crumbling could be forestalled following smoking suspension. Then, at that point the smoking suspension not really settled along with the subject, & one of the smoking discontinuance prescriptions was endorsed. All subjects were given control arrangements twice for the primary month & once each month for the accompanying 2-month follow-up period. Subjects who had CO levels somewhere in the range of 0 & 5 sections for each million were considered as non-smokers.

2.2. Subjects

Subjects who applied to the smoking end out-patient center of our clinic, went through PFT, and finished ≥3 months of the discontinuance program following their induction were remembered for the investigation. Patients who neglected to perform PFT were excluded from the examination.

2.3. Procedures

In the primary meeting, all subjects were gotten some information about their comorbid sicknesses & smoking propensities. Their smoking history was measured in pack-years. The Fagerström test was utilized to evaluate the nicotine reliance scores of the subjects. The Hospital Anxiety & Depression Scale test was done to decide gloom & uneasiness scores. The actual assessments of the subjects were performed by a doctor. PFTs were performed. Obstruction on the PFT was analyzed by GOLD models (ie, post-bronchodilator FEV1 <80% of anticipated & FEV1/FVC <70%). Small aviation route block was analyzed utilizing constrained expiratory stream 25–75% (FEF25–75%) values <65% of anticipated & FEV1/FVC >70%. Subjects who had a check or little aviation route obstacle on PFT were educated that their condition was smoking-related however that reformist decay could be forestalled by smoking end. The study by Fletcher & Peto was displayed for instance. The subjects who had ordinary spirometric estimation were likewise educated with regards to their pneumonic capacity & that they could secure this condition by smoking end.

The carbon monoxide (CO) level in lapsed air was estimated & chest radiographs were taken. A similar doctor performed interviews with subjects, deciphered the PFT, & estimated the CO levels in the lapsed air. Then, at that point a smoking suspension not really settled along with the subject, & one of the smoking end medications was endorsed. Since the public Social Security Institution in Turkey doesn’t take care of the expenses of pharmacologic medicines, the subjects paid for their own treatment costs.

All subjects were given 2 control arrangements for the principal month & when a month from there on for the accompanying 2 months of follow-up. During the control visits, subjects were examined concerning their smoking status, & any antagonistic impacts of the drug. The CO levels in their lapsed air were estimated. Subjects who had CO levels somewhere in the range of 0 & 5 sections for every million (ppm) were viewed as losers, & subjects who had CO levels >6 ppm were considered non-quitters. Subjects who didn’t go to the subsequent visits were additionally viewed as non-slackers. The gathered information were gone into the emergency clinic enrollment framework. Investigations were performed after all subjects had been followed up for 90 days.

2.4. Statistical analysis

Data from the normalized clinical reports were moved to SPSS 17.0 (SPSS, Chicago, Illinois) programming by the
lead analyst. A chi-square test was utilized for examination of absolute factors between gatherings. To look at implies among weaklings & non-losers, a t test was utilized, & illustrative measurements were given as mean ± SD. P < .05 was acknowledged as genuinely critical for all actions. A multivariate strategic relapse investigation was utilized to distinguish the autonomous components that influence smoking discontinuance.

3. Results

An aggregate of 699 patients applied to the smoking suspension out-patient facility of our clinic between January 2012 & September 2014. Of the 639 patients who finished somewhere around 90 days of the suspension program following their permission, 563 subjects who appropriately performed PFTs were remembered for the examination (Figure 1).

The mean age of the 563 subjects was 41.9 ± 12.1 y; 340 (60.4%) were male, & 223 (39.6%) were female. The mean Fagerström score was 6.1 ± 2.3. The mean number of pack-years was 26.9 ± 16.2. The mean CO level was 14.6 ± 8.2 ppm. The mean percent-of-anticipated FEV1 was 88.8 ± 17.5%. The mean nervousness score was 9.7 ± 4.5, & the mean sadness score was 7.7 ± 4.4. Comorbid illnesses were available in 270 subjects (47.9%). 36 subjects (6.3%) had COPD, 29 (5.1%) had asthma, 72 (12.8%) had wretchedness, & 39 (6.9%) had hypertension. PFT showed that 114 subjects (20.2%) had obstructive illness, 111 (19.7%) had little aviation route obstacle, & 11 (2%) had prohibitive sickness discoveries. As per GOLD organizing, of the subjects who had obstructive infection, 94 (82.4%) were stage I-II, & 20 (17.6%) were stage III-IV.

The achievement of smoking end for 90 days was 11.3% (64 of 563). Age (50.8 y versus 40.7 y, P < .001), male sex (71.8% versus 58.9%, P = .042), mean pack-years (34.9 pack-year versus 25.8 pack-year, P < .001), presence of comorbid infections (60.9% versus 46.9%, P = .046), presence of COPD (14% versus 5%, P = .01), & the presence of hypertension (14% versus 6%, P = .034) were altogether higher in the weaklings contrasted & non-losers. There were no contrasts between the 2 gatherings in the CO levels in terminated air, Fagerström score, nervousness score, & despondency score (Figure 1).

At the point when we assessed the cases as per PFT, 22.8% of the subjects with deterrent on PFT quit smoking, while just 8.4% of the subjects without block on PFT quit smoking. The distinction between these gatherings was genuinely critical (P < .001). As indicated by GOLD organizing, 22.3% of the stage I-II subjects & 25% of the stage III-IV subjects quit smoking. The thing that matters was not genuinely critical (P = .79). The level of subjects with obstructive illness on PFT was fundamentally higher (40.6% versus 17.6%, P < .001), & percent-of-anticipated FEV1 (82.9% versus 89.9%, P = .005), FEV1/FVC (72.4 versus 79.0, P < .001), & FEF25–75% (63.2 versus 72.9, P = .008) levels were altogether lower in losers contrasted & non-losers (Table 1). The dissemination of percent-of-anticipated FEV1 was ordinary in slackers (Figure 2).

A sum of 162 subjects (28.8%) went to the subsequent visits after the primary meeting. Among these subjects, 53 (32.7%) got varenicline, 48 (29.6%) got bupropion, & 61 (37.7%) got nicotine substitution treatment. The excess 401 subjects (71.2%) didn’t go to the subsequent visits after the principal meet. Age (45.7 y versus 40.4 y, P < .001); mean pack-years (31.1 pack-years versus 25.2 pack-years, P < .001); & the level of COPD, hypertension, & the presence of obstacle on PFT (P = .044, .045, & .001, separately) were fundamentally higher in subjects who went to the subsequent visits. Moreover, these subjects had essentially lower percent-of-anticipated FEV1, FEV1/FVC, & FEF25–75% on PFT (P = .016, P < .001, & P < .001, separately). Unfavorable impacts of the smoking suspension treatment were seen in 26 subjects (16%) who got treatment.

The smoking discontinuance rate for 90 days was 39.5% in the subjects who got treatment. Age, male sex, mean pack-years, & the presence of block on PFT were altogether higher in the slackers contrasted & the non-weaklings; then again, these subjects had fundamentally lower FEV1/FVC
Table 1:

|                        | All Subjects (N = 563) | Quitters (n = 64; 11.3%) | Non-Quitters (n = 499; 88.7%) | P Value |
|------------------------|------------------------|--------------------------|-------------------------------|---------|
| Age, mean + SD y       | 41.9 ± 12.1            | 50.8 ±12.3               | 40.7 ± 11.6                   | <0.001  |
| Sex                    |                        |                          |                               |         |
| Male                   | 60.4                   | 71.8                     | 58.9                          |         |
| Female                 | 39.6                   | 28.2                     | 41.1                          |         |
| Fagerström score, mean + SD | 6.1±2.3            | 6.0±2.5                  | 6.1±2.3                       | 0.9     |
| Pack-years, mean SD    | 29.9±16.2              | 34.9±17.6                | 25.8±15.8                     | <0.001  |
| CO level, mean + SD ppm| 14.6±8.2               | 14.0±7.5                 | 14.7±8.2                      | 0.51    |
| Comorbidities (%)      | 47.9                   | 60.9                     | 46.9                          | 0.046   |
| Depression (%)         | 12.8                   | 12.5                     | 13                            | 0.90    |
| Asthma (%)             | 5.1                    | 6                        | 5                             | 0.70    |
| COPD (%)               | 6.3                    | 14                       | 5                             | 0.01    |
| Hypertension (%)       | 6.9                    | 14                       | 6                             | 0.034   |
| Mean anxiety score, mean + SD | 9.7±4.5             | 8.6±3.7                  | 9.8±4.5                       | 0.82    |
| Mean depression score, mean + SD | 7.7±4.4             | 8.0±4.2                  | 7.7±4.5                       | 0.25    |
| Obstruction on PFT (%) | 20.2                   | 40.6                     | 17.6                          | <0.00   |
| Restriction on PFT (%) | 2.0                    | 00                       | 2.2                           | 0.23    |
| Small airway obstruction on PFT (%) | 19.7                | 15.6                     | 20.2                          | 0.50    |
| FVC, mean + SD % predicted | 96.3±14.9           | 94.4±18.5                | 96.6±14.4                     | 0.27    |
| FEV, mean + SD % predicted | 88.8±17.5           | 82.9±24.6                | 89.9±16.1                     | 0.005   |
| FEV/FVC, mean + SD L/S | 78.2±11.4             | 72.4±11.9                | 79.0±11.1                     | <0.001  |
| FEF 25-75% mean + SD L/S| 71.7±27.0            | 63.2±32.6                | 72.9±25.9                     | 0.008   |

ppm = parts per million
FEF25-75% =forced expiratory flow during the middle half of the FVC maneuver

(P < .001, P = .005, P = .01, P = .01, & P = .01, separately).

4. Discussion

In this investigation, we discovered that the smoking suspension rate for 90 days was 11.3% for the entirety of the subjects who were conceded to our smoking end facility & 39.5% for the treated subjects. Age, male sex, mean pack-years, presence of comorbid infection, & check on PFT were essentially higher, & PFT levels were fundamentally lower in the subjects who quit smoking. Additionally, the achievement pace of smoking discontinuance following 3 months was essentially higher in subjects with obstructive infection (22.8%), contrasted & subjects without obstructive sickness (8.4%). Given the conflicting outcomes in past investigations, we accept that our present study makes a significant commitment to the writing.

It has been realized that smoking causes COPD, & stopping smoking forestalls COPD progression. Jiménez-Ruiz et al12 have recently resolved whether or not COPD makes the most common way of smoking end simpler. They found that subjects with COPD had more significant levels of nicotine compulsion, contrasted & solid smokers, & these subjects didn’t have higher inspiration for smoking end. In another investigation, creators discovered
Table 2:

|                                | Subjects Who Attended Follow-Up (N = 162) | Quitters (n = 64; 39.5%) | Non-Quitters (n = 98; 60.5%) | P Value |
|--------------------------------|------------------------------------------|--------------------------|----------------------------|---------|
| Age, mean + SD y               | 45.7±13.2                                | 51.1±12.4                | 40.7±11.6                  | <0.001  |
| Sex                            |                                          |                          |                            |         |
| Male                           | 58.6                                     | 73.3                     | 50                         |         |
| Female                         | 41.1                                     | 26.7                     | 50                         |         |
| Mean Fagerström score, mean±SD | 6.2±2.3                                  | 6.0±2.5                  | 6.3±2.3                    | 0.46    |
| Pack-years, mean ±SD ppm       | 31.1±17.8                                | 34.9±17.6                | 25.8±15.8                  | 0.01    |
| Mean CO level, mean + SD ppm   | 14.2±7.8                                 | 13.9±7.4                 | 14.4±8.0                   | 0.73    |
| Comorbidities (%)              | 53.1                                     | 63.3                     | 47                         | 0.052   |
| Depression (%)                 | 12.3                                     | 11.6                     | 12.7                       | >.99    |
| Asthma (%)                     | 5.6                                      | 6.6                      | 4.9                        | 0.70    |
| COPD (%)                       | 9.9                                      | 15                       | 6                          | 0.10    |
| Hypertension (%)               | 10.5                                     | 15                       | 7.8                        | 0.18    |
| Mean anxiety score, mean + SD  | 9.0±4.0                                  | 8.8±3.7                  | 9.2±4.1                    | 0.74    |
| Mean depression score, mean + SD| 7.3±4.0                                  | 8.2±4.2                  | 6.9±3.9                    | 0.26    |
| Obstruction on PFT (%)         | 29.6                                     | 41.6                     | 22.5                       | 0.01    |
| Restriction on PFT (%)         | 1.2                                      | 00                       | 1.9                        | 0.53    |
| Small airway obstruction on PFT%| 18.5                                     | 15                       | 20.5                       | 0.41    |
| FVC, mean ± SD % predicted     | 96.1±16.3                                | 94.2±18.8                | 97.2±14.6                  | 0.28    |
| FEV, mean ± SD % predicted     | 85.9±20.8                                | 82.4±25.0                | 88.1±17.5                  | 0.10    |
| FEV/FVC, mean + SD             | 75.2±12.0                                | 72.1±12.1                | 77.0±11.7                  | 0.01    |
| FEF 25-75% mean + SD L/S       | 65.5±29.5                                | 62.9±33.2                | 67.2±27.0                  | 0.39    |
| Varenicline (%)                | 32.7                                     | 31.6                     | 33.3                       | 0.86    |
| Bupropion (%)                  | 29.6                                     | 31.6                     | 28.4                       | 0.72    |
| NRT (%)                        | 37.7                                     | 40                       | 34.3                       | 0.50    |
| Adverse Effects (%)            | 16                                       | 11.8                     | 18.6                       | 0.37    |

ppm = parts per million
FEF 25-75% = forced expiratory flow during the middle half of the FVC maneuver
NRT = nicotine replacement therapy

...that subjects who quit smoking had further developed age & lower percent-of-anticipated FEV1 & FEV1/FVC ratios.13 Past examinations have yielded conflicting outcomes in regards with the impact of illuminating subjects about a hindrance, which is controlled by spirometry, on smoking suspension achievement rates. Misfortune et al19 directed perhaps the most punctual study in this field toward the finish of the 1970s. This examination showed that offering data to subjects about early aviation route, not really settled utilizing definite aspiratory capacities tests, made no huge commitment to the smoking end achievement rate in youthful grown-ups without the drawn out help of a doctor.19 Other investigations demonstrated that the smoking suspension achievement rate was higher in subjects with pathology on PFT.27–29 Two randomized controlled examinations during the 1990s likewise tracked down that unusual PFT discoveries added to the accomplishment of smoking cessation.32,33 In a later randomized controlled investigation, the creators presumed that low spirometric values didn't expand the accomplishment of smoking cessation.19

On the other hand, numerous patients with COPD proceed with their lives for quite a while without understanding their condition. Along these lines, spirometric estimation is significant for patients who apply to smoking end facilities.

Górecka et al13 completed a forthcoming, randomized controlled study& found that subjects with moderate as well as extreme block had the most elevated achievement rate. Moreover, their outcomes showed that subjects with old age & subjects with a lower level of smoking had a superior achievement rate. In this examination, the writers...
educated the subjects about spirometry, furnished them with booklets, & reexamined the subjects toward the finish of the 1-y period.\textsuperscript{13} In a comparative report, subjects went through spirometric estimations, & the subjects with block were educated with regards to their conditions & planned for a development. After one year, the achievement pace of smoking end was altogether higher in those subjects with impediment & the subjects with less nicotine addiction.\textsuperscript{14} Two different examinations additionally found comparable results.\textsuperscript{15,16} In these investigations, spirometric estimations were performed, & the accomplishment of smoking discontinuance (without pharmacologic treatment) over the long haul, was assessed. A review\textsuperscript{21} showed that there is inadequate proof to derive that spirometry expands the achievement pace of smoking end. In 2008, Parkes\textsuperscript{18} performed spirometric estimations on 561 smokers. For the principal gathering of subjects, the lung age was determined by the investigation by Fletcher,\textsuperscript{2} & subjects were educated with regards to the outcomes. Then again, just spirometric estimations were performed for subjects in the subsequent gathering, & lung age was not determined. Toward the finish of the primary year, the accomplishment of smoking end was 13.6% in the main gathering & 6.4% in the benchmark group. The creators inferred that computing lung age & disclosing it to subjects expanded the achievement pace of smoking discontinuance. The Cochrane meta-analysis,\textsuperscript{22} which analyzed the impacts of as of late announced biomedical danger determiners on the smoking discontinuance achievement rate, showed that the study by Parkes et al\textsuperscript{18} was the just one demonstrating the commitment of PFTs to smoking suspension achievement rates; in any case, there was not adequate proof to make a positive commitment.

Our examination was not a randomized controlled investigation. All subjects who had impediment on PFT were educated with regards to their condition, & all subjects who had typical spirometry results were likewise educated that they had ordinary outcomes. The achievement of 3-month smoking discontinuance was 22.8% in subjects with unusual PFT discoveries & 8.4% in subjects with typical PFT discoveries. This distinction was measurably huge (P < .001). In any case, smoking discontinuance rates were not distinctive between the subjects with gentle to direct obstacle (GOLD I-II) & the subjects with serious to extremely extreme impediment (GOLD III-IV) (22.3% versus 25%). This outcome showed that having indications as well as having been educated with regards to their conditions influenced subjects’ smoking end achievement. Like Görcke et al,\textsuperscript{13} we found that subjects who quit smoking had further developed age & lower percent-of-anticipated FEV1, FEV1/FVC, & FEF25–75%, contrasted & non-slackers. As opposed to the discoveries of Görcke et al\textsuperscript{14} & Bednarek et al,\textsuperscript{14} the extent of weighty smokers was higher in the slackers. At the point when we considered comorbid infections, the frequencies of COPD & hypertension were fundamentally higher in the slackers, though there were no critical contrasts in the recurrence of wretchedness & tension/melancholy scores. Additionally, Fagerström\textsuperscript{34} have tracked down that the presence of comorbid infections expanded the achievement of smoking end. Calculated relapse study showed that age & the presence of deterrent on PFT were free factors for smoking suspension achievement. It isn’t unexpected to discover old age & lower spirometric levels coinciding together, since the rate of COPD is higher in guys & more established people.\textsuperscript{35}

As indicated by a meta-examination which assessed smoking suspension methodologies in subjects with COPD, pharmacologic treatment with conduct treatment shows a prominent expansion in the achievement rate.\textsuperscript{10} In our investigation, the general achievement pace of smoking discontinuance was 11.3%, while this rate was 39.5% for the subjects who got pharmacologic treatment & gone to subsequent meet-ups. It appears to be that the subjects who got pharmacologic treatment that was endorsed by the going to doctor & paid for the treatment costs not set in stone to succeed. Age, mean pack-years, comorbid infections, & the presence of check on PFT were altogether higher in these subjects. Our middle is a unit of a public medical clinic, & patients who apply to our center have low salaries. Regardless of the way that all subjects were educated with regards to the significance of pharmacologic treatment, they couldn’t take care of the expenses of drugs, & thus, such subjects didn’t appear for follow-up assessments. Concerning the treated subjects, age, male sex, mean pack-years, & the presence of impediment were higher in the weaklings, while the FEV1/FVC was lower contrasted & non-losers. This outcome likewise showed that these subjects not really settled with regards to smoking suspension.

The limits of our exploration are that it was a solitary place study, so the outcomes can’t be summed up, & that it was additionally a review accomplice study, so the subjects who didn’t appear for follow-up visits were viewed as non-weaklings. A portion of the subjects who didn’t appear for follow up visits may have stopped however were thought to be non-slackers.

5. Conclusion

Advanced age & the presence of deterrent on PFT increment the achievement of smoking discontinuance. All patients who apply to the smoking suspension out-patient center ought to have aspiratory work tests performed & be educated with regards to their condition. More randomized controlled studies are required regarding this matter. We accept that if all patients are upheld & supported more at smoking discontinuance facilities & the expenses of their pharmacologic treatment are covered by the Social Security
Institution, smoking end achievement will increment.

6. Source of Funding
None.

7. Conflict of Interest
None.

References
1. Mathers CD, Loncar D. Projections of global mortality & burden of disease from 2002-2030. PLoS Med. 2006;3(11):e442.
2. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1(6077):1645–8.
3. Buist AS, Sexton GJ, Nagy JM, Ross BB. The effect of smoking cessation & modification on lung function. Am Rev Respir Dis. 1976;114(1):115–22.
4. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50-years’ observations on male British doctors. Br Med J. 2004;328(7455):1519.
5. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kaner RE. Connett JE Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomised clinical trial. Ann Intern Med. 2005;142(4):233–9.
6. Celi BR, Macnee W. Standards for the diagnosis & treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–46.
7. Clinical Practice Guideline Treating Tobacco Use & Dependence 2008 Update Panel, Liaisons, & Staff. A clinical practice guideline for treating tobacco use & dependence: 2008 update. A U.S Public Health Service Report. Am J Prev Med. 2008;35(2):158–76.
8. Miranda JAR, Ruiz CAJ, Rebollo JCS. Smoking cessation: update. Clin Palm Med. 2013;20(3):129–36.
9. Zwar NA, Mendelsohn CP, Richmond RL. Supporting smoking cessation: clinical review. Br Med J. 2014;348:g7535.
10. Strassmann R, Bausch B, Spaar A, Kleijnen J, Braendli O, Puhan MA. Smoking cessation interventions in COPD: a network meta-analysis of randomised trials. Eur Respir J. 2009;34(3):634–40.
11. Jiménez-Ruiz CA, Masa F, Miravitlles M, Gabriel R, Viejo JL, Villasante C, et al. Smoking characteristics: differences in attitudes & dependence between healthy smokers & smokers with COPD. Cystic Fibrosis. 2001;119(5):1365–70.
12. Kupiainen H, Kinnula VL, Lindqvist A, Postma DS, Boezen HM, Laitinen T, et al. Successful Smoking Cessation in COPD: Association with Comorbidities and Mortality. Palm Med. 2012;45(11):115-872012/2705748.
13. Görecka D, Bednarek M, Nowiński A, Pucięska E, Goljan-Geremek A, Zieliński J. Diagnosis of airflow limitation combined with smoking cessation advice increases stop-smoking rate. Chest. 2003;123(6):1916–23.
14. Bednarek M, Górecka D, Wielgomas J, Czajkowska-Malinowska M, Regula J, Mieszko-Filipizyk G, et al. Smoking with airway obstruction are more likely to quit smoking. Thorax. 2006;61(10):869–73.
15. Cloetj J, Gómez-Arbonés X, Ciriá C, Balbad JM. Spirometry is a good method for detecting & monitoring chronic obstructive pulmonary disease in high-risk smokers in primary health care. Arch Bronconeumol. 2004;40(4):155–9.
16. Statelis G, Misiad P, Jakobsson P, Zetterström O. The impact of repeated spirometry & smoking cessation advice on smokers with mild COPD. Scand J Prim Health Care. 2006;24(3):133–9.
17. Parkes G, Greenhalgh T, Griffin M, Dent R. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. Br Med J. 2008;336(7644):598–600.
18. Loss RW, Hall WJ, Speers DM. Evaluation of early airway disease in smokers: cost effectiveness of pulmonary function testing. Am J Med Sci. 1979;278(1):27–37.
19. Buffels J, Degrève J, Decrém器具 M, Heyrman J. Spirometry & smoking cessation advice in general practice: a randomised clinical trial. Respir Med. 2006;100(11):2012–7.
20. Wilt TJ, Niewoehner D, Kane RL, Macdonald R, Joseph AM. Spirometry as a motivational tool to improve smoking cessation rates: a systematic review of the literature. Nicotine Tob Res. 2007;9(1):21–32.
21. Bize R, Burnand B, Mueller Y, Rége-Walther M, Camain JY, Cornuz J. Biomedical risk assessment as an aid for smoking cessation (Review). Cochrane Database Syst Rev. 2012;12(12):CD004705. doi:10.1002/14651858.CD004705.pub4.
22. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86(9):1119–27.
23. Zigmund AS, Snait RP. The hospital anxiety & depression scale. Acta Psychiatr Scand. 1983;67(6):361–70.
24. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A. Standardisation of spirometry. Series ATS/ERS Task Force: Standardisation of Lung Function Testing. Eur Respir J. 2005;26(2):319–38.
25. Groman E, Bernhard G, Blauensteiner D, Kunze U. A harmful aid to stopping smoking. Lancet. 1999;353(9151):466–7.
26. Groman E, Bayer P. A combination of exhaled carbon monoxide (CO) & the Fagerstrom Test for Nicotine Dependence (FTND) is recommended to complete information on smoking rates in population-based surveys. Soc Praventiv Med. 2000;45(5):226–8.
27. Petty TL, Prierson DJ, Dick NP, Hudson LD, Walker SH. Follow-up evaluation of a prevalence study for chronic bronchitis & chronic airway obstruction. Am Rev Respir Dis. 1976;114(5):881–90.
28. Hepper NG, Drage CW, Davies SF, Rupp WM, Lamotte J, Schoenfelder PG, et al. Chronic obstructive pulmonary disease: a community oriented program including professional education & screening by a voluntary health agency. Am Rev Respir Dis. 1980;121(1):97–104.
29. Baker TR, Oscherwitz M, Corlin R, Jarboe T, Teisch J, Nichaman MZ. Screening & treatment program for mild chronic obstructive pulmonary disease. JAMA. 1970;214(8):1448–55.

Author biography
Farzana Mustafa, Assistant Professor
Abdul Hai Mohammad, House Surgeon

Cite this article: Mustafa F, Mohammad AH. A qualitative study of pulmonary function tests between smokers and non smokers in Telangana state. Indian J Clin Anat Physiol 2021;8(3):219-225.